Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new therapy boost joy in Spanish-Speakers with depression?

NCT ID NCT07493369

Symptom relief Sponsor: Southern Methodist University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a therapy called Positive Affect Treatment (PAT) for Spanish-speaking adults with depression, anxiety, and low positive affect (a lack of joy or interest). Twelve participants will attend 15 therapy sessions over about 4 months, focusing on pleasant activities, positive thinking, and savoring good experiences. The goal is to see if the therapy is feasible and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Positive Affect Treatment (PAT) - a behavioral therapy involving pleasurable activities, cognitive exercises, and savoring techniques
What this could lead to
If successful, this could provide a new therapy option for Spanish-speaking individuals with depression and anxiety who struggle with low positive affect.
What could go wrong
This is a very small pilot study with only 12 participants and no control group, so results may not be generalizable. It is early-stage and focuses on feasibility, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Spanish as their preferred language for therapy * Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression, greater to or equal to 6 for anxiety, or greater to or equal to 10 for stress on the Depression, Anxiety, and Stress Scale; and scores of greater than or equal to 5 on any Sheehan Disability Scale subscale. * Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion Exclusion Criteria: * Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes) * Active suicidal ideation * Lifetime history of bipolar disorder, psychosis, cognitive impairment, or organic brain damage * Substance abuse in the last 6 months or dependence within last 12 months. * Greater than 11 cigarettes per week or nicotine equivalent before age 15 * History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine) * Pregnancy * Bupropion, dopaminergic or neuroleptic medications use in the past 6 months * Refusal of video/audio-taping * Prior participation in previous waves of this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anhedonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anhedonia anxiety anxiety disorder depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anhedonia Anxiety Depression in adults

Contacts and locations

Locations

  • Southern Methodist University

    Dallas, Texas, 75205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.